Social Anxiety Disorder – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of social anxiety disorder (SAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of SAD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s SAD forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SAD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts two SAD patient populations, as follows:
- Total 12-month prevalent cases.
- Total 12-month prevalent cases with comorbid 12-month major depressive disorder.
Note: coverage may vary by country.
Table of contents
- Social Anxiety Disorder - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Prevalence of Social Anxiety Disorder per 1,000 Among People Aged 20+ in 2021 and 2041
- Prevalence of Social Anxiety Disorder per 1,000 Among People Aged 20+ in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Social Anxiety Disorder over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Social Anxiety Disorder over the Next 20 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.